October 10, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top technical trading patterns and these stocks are the most likely to trade Up in the coming weeks. TEKELEC (NASDAQ:TKLC), SALIX PHARMACEUTICALS LTD (NASDAQ:SLXP), KNOLL INC (NYSE:KNL), ENZO BIOCHEM INC (NYSE:ENZ), MEDICINES COMPANY (NASDAQ:MDCO), DAWSON GEOPHYSICAL CO (NASDAQ:DWSN) are all expected to go Up as Bullish signals have been generated by top technical trading patterns. We monitor these patterns: Support Break, Support Reversal, Breakaway Gap, Measured Gap, Exhaustion Gap, Resistance Break, Resistance Reversal, Saucer Reversal, Volume Climax, Volume Trend, Fibonacci Reversal, Consolidation Breaks, Trend Line Break,Trend Line Reversal, Candles, Golden Crosses, Death Crosses and more. The chart below displays the stocks expected to go Up along with pattern, strategy and strength ratings.

     Symbol     Company                             Strategy                            Pattern Name            Strength  
     TKLC       TEKELEC                             Reversal (Stocks) DWC               Trend Line Break(5+)     5         
     SLXP       SALIX PHARMACEUTICALS LTD           Breakout (Stocks) DO                Trend Line Break(5+)     5         
     KNL        KNOLL INC                           Breakout (Stocks) DO                Broadening Bottom       1         
     ENZ        ENZO BIOCHEM INC                    Reversal (Stocks) DWC               Trend Line Break(3)     5         
     MDCO       MEDICINES COMPANY                   Breakout (Stocks) DO                Breakaway Gap           1         
     DWSN       DAWSON GEOPHYSICAL CO               Reversal (Stocks) DWC               Broadening Reversal     1

Chart Pattern Recognition is based on a 20-year patterns database. This database is used to determine pattern strength for patterns as they appear. There is no optimization and the pattern signals never change. For each pattern variation, we record accuracy and profitability statistics in a patterns database. From this information, we are able to define strength ratings from 1 to 5. The '1' rating shows ALL patterns while a '5' rating shows the best patterns according to profitability. Each pattern has its own strength rating factors. The result is an automatic ranking system that allows us to only show the BEST patterns. You can see that, at Strength 5, virtually all the patterns are profitable. The pattern strength rating system separates the most profitable patterns. The specific technology used to make these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/sw/ot.php

TEKELEC (NASDAQ:TKLC) - Tekelec engages in the design, development, manufacture, marketing, sale, and support of telecommunications products and services. Its EAGLE 5 signaling platform includes Signal Transfer Point functionality for signaling system 7 (SS7) and SIGTRAN (SS7 over IP) traffic; a number portability application for number portability solutions in mobile and fixed networks, such as voice services, short message service, multimedia message services, and prepaid services; flexible routing applications for optimization of a service provider's home location register, resources, and voicemail systems; and short message routing. The companys signaling platform, EAGLE XG, consists of Service Broker application for service mediation and orchestration of current and next generation services; a SIP Signaling Router for implementation of core session initiation protocol (SIP) signaling within voice over IP and IP multimedia subsystem networks and for the call session control function; and ENUM Server application for implementation of electronic number mapping support in IP networks. The EAGLE 5 and EAGLE XG offer applications for integrated data collection used in concert with the companys Integrated Applications Solution (IAS), a real-time performance management and monitoring network application. IAS delivers monitoring plus the network visibility required to ensure that traffic is managed properly and routed in the effective manner. In addition, Tekelec provides a Mobile Messaging Product Family of applications for network-based short message service, and control of unwanted text messages. The company also offers a range of professional services, including installation and training services; and customer post-warranty support services. It sells its products through direct sales force, sales agents, partnerships, and distributor relationships worldwide. The company was founded in 1971 and is headquartered in Morrisville, North Carolina.

SALIX PHARMACEUTICALS LTD (NASDAQ:SLXP) - Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The companys marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; OsmoPrep and Visicol tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also comprise Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer, and gastro-esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, the company has products under development for the treatment of irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, ulcerative colitis, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; CedarsSinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; Photocure ASA; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina.

KNOLL INC (NYSE:KNL) - Knoll, Inc., together with its subsidiaries, engages in the design, manufacture, and sale of workplace furnishings, textiles, and fine leathers for the workplace and home. The company offers office systems products, which are modular and moveable workspaces with functionally integrated panels, work surfaces, desk components, pedestal and other storage units, power and data systems, and lighting. It also provides specialty products comprising high image side chairs, sofas, desks, tables, textiles, accessories, leathers, and related products; seating products; and files and storage products, such as lateral files, mobile pedestals and other storage units, bookcases, and overhead storage cabinets. In addition, Knoll offers desks, case goods, and tables. The company serves Fortune 1000 companies, governmental agencies, and other organizations in various industries, including primarily education, healthcare, and hospitality. It sells its products primarily through its direct sales representatives and independent dealers in the United States, Canada, and Europe. The company was founded in 1938 and is headquartered in East Greenville, Pennsylvania.

ENZO BIOCHEM INC (NYSE:ENZ) - Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.

MEDICINES COMPANY (NASDAQ:MDCO) - The Medicines Company operates as a global pharmaceutical company with a focus on advancing the treatment of critical care patients. The company markets Angiomax for use in patients undergoing coronary angioplasty; and Cleviprex, an injectable emulsion for the reduction of blood pressure. Its developing products include Cangrelor, an antiplatelet agent, which is in phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin that is in phase III clinical trial acts as an antibiotic for the treatment of serious gram-positive bacterial infections, including ABSSSI; and Argatroban, a phase III and NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The Medicines Companys developing products also include CU2010, which is in phase I clinical trial that acts as a serine protease inhibitor for the reduction of blood loss during surgery; and ApoA-I Milano, a phase I clinical trial product for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS. The company sells its products through sales representatives and managers. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

DAWSON GEOPHYSICAL CO (NASDAQ:DWSN) - Dawson Geophysical Company provides onshore seismic data acquisition services in the United States. The company acquires and processes 2-D, 3-D, and multi-component seismic data for various clients, ranging from oil and gas companies to independent oil and gas operators, as well as providers of multi-client data libraries. The 2-D method involves the collection of seismic data in a linear fashion to generate a single plane of subsurface seismic data. The 3-D method produces a volume of seismic data, which produces more precise images of the earths subsurface. As of December 31, 2009, it operated 11 3-D seismic data acquisition crews in the lower 48 states of the United States and a seismic data processing center. The company was founded in 1952 and is headquartered in Midland, Texas with additional offices in Houston, Denver, Oklahoma City, and Michigan.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net

Like: 👍